Business
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
Experienced industry leader brings extensive expertise in leading breakthrough therapies through ...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs\n\n\n\n\n\n\n\n Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval\n \n\n\n\n\n\n Satellos Bioscience Inc\n \n . (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer (“CDO”) and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (Nasdaq: VRTX). She joins Satellos from Generation Bio (Nasdaq: GBIO), where she most recently served as Chief Operating Officer.\n \n\n “Bringing Ms. Paone on board to the executive team is incredibly exciting given her track record of charting the path to regulatory approval for breakthrough medicines,” said Frank Gleeson, Satellos co-founder and CEO. “With our two clinical studies in DMD advancing in adult and pediatric populations, the possibility of pursuing regulatory approval for SAT-3247 in the future is beginning to come into view. The appointment of Ms. Paone is not only timely, but also reflects our confidence in our expanding set of clinical data.”\n \n\n At Generation Bio, Ms. Paone led the company’s growth from start-up to a development-ready organization, shaping key business functions, including regulatory strategy, quality, CMC, technical operations, and program management. She was also part of the executive team responsible for a series of equity financings over four years, including a successful IPO and a strategic partnership with Moderna. Prior to Generation Bio, she spent more than a decade at Vertex, most recently as Vice President, Head of North American Regulatory Affairs Strategy, where she led regulatory efforts for multiple novel small molecule cystic fibrosis therapies, including Kalydeco and Orkambi. Earlier in her career, she held roles at Merck & Co. and Millenium Pharmaceuticals, Inc. Ms. Paone holds an MBA from Bentley College, an MS in Organic Chemistry from Yal...